Lord, Abbett & Co
KDNY

Lord, Abbett & Co’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Lord, Abbett & Co’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-337,698
Closed -$4.63M – 703
2020
Q1 		$4.63M Buy
+337,698
New +$3.99M 0.02% 546
2015
Q3 		– Sell
-32,881
Closed -$4.99M – 976
2015
Q2 		$4.99M Buy
+32,881
New +$5.43M 0.01% 774

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Lord, Abbett & Co's KDNY Position: Q2 2020 in Review

Lord, Abbett & Co sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2020, closing a stake of 337,698 shares — an estimated $4.63M sold.

Lord, Abbett & Co first reported a position in KDNY in Q2 2015 and held it in 2 quarters. The position peaked at $4.99M in Q2 2015. 90 funds tracked by Wall St. Rank hold KDNY as of Q2 2020.

  • Lord, Abbett & Co reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Lord, Abbett & Co sold 337,698 Chinook Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $4.63M.
  • Lord, Abbett & Co first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 2 quarters.
  • Lord, Abbett & Co's Chinook Therapeutics, Inc. Common Stock position peaked at $4.99M in Q2 2015.
  • 90 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Lord, Abbett & Co's 13F filing for Q2 2020, filed 14 Aug 2020.